Trial Profile

Phase IIb trial of a high-dose, continuous delivery formulation of subcutaneously administered levodopa/carbidopa (ND0612H) in patients with Parkinson's disease.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Nov 2015 Planned initiation date changed from 1 Jul 2015 to 1 Dec 2015.
12 Nov 2015 According to the media release of NeuroDerm Ltd., this trial will be initiated by the end of 2015 or in the beginning of 2016.
12 Nov 2015 According to the media release of NeuroDerm Ltd., the company has incorporated the written feedback received from U.S. Food and Drug Administration (FDA). Also, this trial will be conducted at centers in Israel, E.U and U.S.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com